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The leishmaniases are neglected tropical diseases widespread throughout the globe, 
which are caused by protozoans from the genus Leishmania and are transmitted by 
infected phlebotomine flies. The development of a safe and effective vaccine against 
these diseases has been seen as the best alternative to control and reduce the number 
of cases. To support vaccine development, this work has applied an in silico approach 
to search for high potential peptide epitopes able to bind to different major histocom-
patibility complex Class I and Class II (MHC I and MHC II) molecules from different 
human populations. First, the predicted proteome of Leishmania braziliensis was
compared and analyzed by modern linear programs to find epitopes with the capacity 
to trigger an immune response. This approach resulted in thousands of epitopes
derived from 8,000 proteins conserved among different Leishmania species. Epitopes 
from proteins similar to those found in host species were excluded, and epitopes from 
proteins conserved between different Leishmania species and belonging to surface 
proteins were preferentially selected. The resulting epitopes were then clustered, to 
avoid redundancies, resulting in a total of 230 individual epitopes for MHC I and 2,319 
for MHC II. These were used for molecular modeling and docking with MHC structures 
retrieved from the Protein Data Bank. Molecular docking then ranked epitopes based 
on their predicted binding affinity to both MHC I and II. Peptides corresponding to 
the top 10 ranked epitopes were synthesized and evaluated in vitro for their capacity 
to stimulate peripheral blood mononuclear cells (PBMC) from post-treated cutaneous 
leishmaniasis patients, with PBMC from healthy donors used as control. From the
10 peptides tested, 50% showed to be immunogenic and capable to stimulate the 
proliferation of lymphocytes from recovered individuals.
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inTrODUcTiOn
The leishmaniases constitute an important group of neglected 
tropical diseases (1), which affect and impact “the bottom bil-
lion” of people living in poverty by inducing disfiguration, loss 
of productivity, and a burden of 3.3 million disability-adjusted 
life years (DALY) (2–4). It is estimated that one-quarter of the 
world’s population, 1.7 billion people, are living in risk areas 
for leishmaniasis (5). Until recently, 98 countries have reported 
cases of leishmaniasis with 0.7–1.2 and 0.2–0.4 million cases 
reported annually of cutaneous leishmaniasis (CL) and visceral 
leishmaniasis (VL), respectively (6). The leishmaniases are 
caused by protozoans from the genus Leishmania, transmitted 
to humans and other mammals by phlebotomine sand fly bites 
(7). These diseases have multiple clinical forms and the main 
ones are CL, widely distributed among targeted populations and 
which affects the skin and mucous; VL, the more lethal form if 
not treated, which affects mainly the reticuloendothelial system 
of the liver and the spleen; and mucocutaenous leishmaniasis 
(MCL), which affects the mucous and has a poor prognosis. In 
Brazil, most of CL cases are caused by Leishmania braziliensis. 
The disease is found in different regions (8), but many patients 
experience spontaneous cure that is associated with IFN-γ 
production (9). Diverse strategies are being used to control 
the leishmaniasis, namely, the control of infected animals and 
vectors and the chemotherapy of affected individuals. These 
approaches, however, have a high cost and can also induce 
resistance in parasites and vectors (10). Therefore, a safe and 
effective vaccine against human leishmaniasis is urgent to 
address these issues.
Vaccines against Leishmania spp. have the major task of 
correctly activating the immune system to develop a protec-
tive response composed mainly by CD4+ and CD8+ T cells, 
producing and secreting IFN-γ. This response has been associ-
ated with disease control, macrophage activation, and parasite 
elimination from the host (11–13). Our previous data show that 
cells from patients infected with L. braziliensis produce high 
amounts of IFN-γ after stimulation with whole lysed parasite 
(14, 15). To initiate cellular response, dendritic cells (DCs), 
which are specialized antigen-presenting cells (APCs), have the 
unique capacity of priming naive T cells by presenting peptide 
antigens bound to major histocompatibility proteins (MHCs), 
co-stimulating and secreting cytokines, and thus mounting a 
T cell response against Leishmania spp. Some Leishmania spe-
cies, e.g., Leishmania amazonensis and Leishmania mexicana, 
may fail to activate DCs, and consequently, no effective T cell 
response is mounted (16, 17). L. braziliensis is capable of activat-
ing DCs and inducing a protective immune response (18). It is 
estimated that each mature DC expresses 106–107 MHC Class II 
(MHC II) and 105 MHC Class I (MHC I) molecules (19). The 
activation of CD8+ T cells is a result of the specific engagement 
of 9-mer-peptide to MHC I proteins (9-mer-p-MHC Class I), 
while CD4+ T cells are activated by 15-mer-peptides bound to 
MHC II (15-mer-p-MHC Class II).
There is no such thing as an ideal antigen, and the search 
for antigens that could generate immunogenic epitopes for a 
potential vaccine against Leishmania spp. is thus critical. In this 
sense, reverse vaccinology has been constantly increasing its 
value, and now diverse in silico approaches are available for the 
identification of potential antigens and epitopes for vaccines. 
Since experimental methods are difficult and time consuming, 
reverse vaccinology using in silico methods has narrowed the vast 
amount of molecules to be tested, increasing the odds of finding 
better candidates (20). In addition, many pathogen genomes 
and proteomes are currently available in public data banks and 
can be assessed regarding their potential antigen diversity and 
variability. Thus, sequence- and structure-based methods inves-
tigating the binding affinity of peptides to MHC I and MHC II 
molecules and other parameters may aid in the search for new 
antigens in order to support vaccine development (21). John 
et al. (22) have used only sequence-based methods to search for 
different epitopes in the predicted proteome of Leishmania spp. 
Agallou et al. (23) have recently reported the construction of a 
multi-epitope peptide vaccine against leishmaniasis by analyzing 
four known proteins from Leishmania infantum. In this context, 
we hypothesized that a combination of modern sequence and 
protein structure algorithms would help the search, within the 
whole predicted proteome from L. braziliensis, for potential 
immunogenic epitopes with high affinity for both human MHC 
I and MHC II. Thus, the aim of this work was to combine robust 
in  silico approaches in the search for potential immunogenic 
T cell epitopes, based on the proteome of L. braziliensis, for the 
development of an anti-Leishmania vaccine.
resUlTs
linear epitope Prediction
With the goal of developing a peptide vaccine based on in silico 
approaches, many studies have shown its feasibility, and different 
attempts have been carried out in order to find good epitopes 
capable of stimulating the immune system and its memory 
arm (21, 24–26), but these mainly rely on computational tools, 
which focus on epitope prediction. Here, we have developed an 
in silico pipeline combining the linear prediction of epitopes with 
a sequence of structural refinements to confirm the potential of 
some epitopes to bind to MHC molecules and thus stimulate the 
immune system. Several computational tools were applied with 
the goal of minimizing the number of candidate epitopes identi-
fied as well as maximizing their potential as inducers of protective 
immunity. The whole strategy used can be seen in the workflow 
described in Figure 1.
The initial epitope prediction tools used here (NETMHC and 
NETCTL) were selected based on two criteria, namely, predictors 
of MHC I and MHC II binding affinity and predictors in which 
their accuracy and performance applied to trypanosomatid 
protein sequences have already been assessed by Resende et al. 
(27). NETMHC and NETCTL were then used to predict MHC 
I-binding epitopes, and NETMHC Class II was used for a MHC II 
prediction. For each allele supertype, the epitopes predicted were 
those classified by the tools as strong binders. Simultaneously, 
different sets of sequence analysis were performed in order 
to exclude all epitopes that belonged to proteins conserved in 
humans and mice, so as to avoid potential autoimmune epitopes; 
select epitopes belonging to proteins conserved between different 
FigUre 1 | Methodology flowchart used in this work. TriTrypDB was used to retrieve the predicted proteome of Leishmania spp. (a). Predicted proteome 
sequences were analysed by different methods (B). EpitopeDB relational database was created, and managed using MySQL as database management system. 
Parsers and algorithms in PERL and SQL languages were developed in order to access and integrate the results (c). Data was clustered (D). Clustered data was 
used for molecular modeling (e).
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TaBle 1 | number of predicted epitopes by bioinformatics tools.
allele supertype Mhc class i prediction
neTMhc neTcTl
number of predicted epitopes
HLA-A1 17 556
HLA-A2 181 685
HLA-A3 86 579
HLA-A24 18 444
HLA-A26 61 515
HLA-B7 20 1,620
HLA-B27 229 1,092
HLA-B44 31 466
HLA-B58 14 753
allele supertype Mhc class ii prediction
neTMhc class ii
number of predicted epitopes
HLA-DPA 7,021
HLA-DPB 1,558
HLA-DQA 14,762
HLA-DRB 41,212
4
e Silva et al. T Cell Epitopes in the Proteome of Leishmania braziliensis
Frontiers in Immunology | www.frontiersin.org August 2016 | Volume 7 | Article 327
Leishmania species, potentially able to induce an immune response 
against multiple species; select epitopes that came from proteins, 
which were predicted as extracellular or secreted and having a 
maximum of one trans-membrane domain, therefore selecting 
epitopes from proteins easier to express and which should be 
generally exposed to the host immune system. The number of 
predicted epitopes for both MHC I and MHC II derived from 
these predictions, and the allele supertypes, are summarized 
in Table 1. If all predictions for different MHC alleles are con-
sidered, the total number of epitopes found in this stage is 657, 
6,710, and 64,553, for NETMHC, NETCTL, and NETMHCII, 
respectively. Next, as the total epitope prediction includes some 
degree of redundancy, a clustering step was performed, consider-
ing the sequence similarity among the predicted epitopes, and 
this analysis resulted in 168 groups for MHC I and 2,138 groups 
for MHC II. Subsequently, each group was dismembered to reveal 
the exact sequence of each epitope, resulting in 230 individual 
epitopes for MHC I and 2,319 epitopes for MHC II.
Fitting linear epitopes into Mhc 
structures
As the main objective of this work was to select predicted epitopes 
with a good binding affinity to a large number of MHC receptor 
alleles, a molecular modeling approach was used aiming to find 
the most in  silico stable epitope +  allele complexes. Structures 
from 33 different alleles of MHC I (21) and MHC II (12) were 
downloaded and processed as described in the Section “Materials 
and Methods,” prior to modeling their interaction with the indi-
vidual predicted epitopes. The sequence of steps followed can be 
found in Figure 2. The first step consists of the replacement of 
the co-crystallized peptide (present at each downloaded struc-
ture) for each one of the predicted epitopes. The total number of 
complexes is composed of 4,830 complexes for MHC I (21 MHC 
I alleles times 230 predicted epitopes) and 27,828 complexes 
for MHC II receptor (12 MHC II alleles times 2,319 predicted 
epitopes). As the overall combinations of all the MHC structures 
and predicted epitopes achieved an impressive number of 32,658 
complexes, a distributed computing strategy was adopted to 
process this large-scale problem in a feasible time.
With all the 32,658 complexes (receptor + epitope) generated 
and their respective epitopes energetically relaxed, the molecular 
docking could be started. This was carried out using the Rosetta’s 
FlexPepDock protocol. However, during the development of this 
molecular modeling protocol, several preliminary evaluations 
were made in order to find a good trade-off between precision 
and computational demand. First of all, it has been noticed that 
the use of Rosetta’s FixBB protocol to replace the co-crystallized 
peptide by the predicted epitopes generates typical unstable 
structures, with high positive Interface scores (Isc). Therefore, 
three complexes (predicted epitope + allele), that had the best, 
a regular and the worst Isc values, based solely on the structures 
obtained by FixBB, were selected and submitted to the Rosetta’s 
Relax protocol. This step was performed to verify if the Relax 
protocol could stabilize the selected prediction in more favora-
ble conformations. The Relax protocol results can be found at 
Figure S1 in Supplementary Material. It is possible to notice an 
increase in affinity of the complexes (predicted epitope + MHC 
receptor) after the relaxing step.
Filtering epitope–Mhc complexes
After the analyses performed previously, there were still an 
impracticable number of complexes (32,658) to be used as input 
for Rosetta’s FlexPepDock protocol. This universe of complexes 
demands a computational effort that is not feasible even using a 
computational grid environment. Thus, a filtering strategy had 
to be adopted in order to select the most promising predicted 
epitopes to the largest possible number of MHC receptor alleles. 
First, knowing that epitopes containing 9 residues (MHC I) can 
be windows of 15-residue epitopes (MHC II), the epitopes from 
the Class I prediction were matched with the Class II epitopes in 
order to find windows of Class I and Class II epitopes. A total of 
385 pairs of 15-residue epitopes and their respective 9-residue 
windows were found.
The filtering strategy required the Isc scores derived from 
the calculation of the whole set of epitope + allele complexes, 
computed using the Rosetta’s Relax protocol (called rescore 
procedure, as detailed in the Section “Materials and Methods”). 
These Isc scores were used to estimate the frequency that each 
predicted epitope appears on the list of top 30% ranked candi-
dates for all available MHC structures (Figure 3). If a 15-residue 
epitope has a good affinity for a MHC II allele, at the top 30% 
best scored epitopes for each target structure, and its 9-residue 
window also has a good affinity for a MHC I allele, this “pair” 
of predicted epitopes (MHC II and MHC I) might be a good 
candidate for better immunogenic properties. The 385 pairs 
of 15-residue epitopes and their respective 9-residue windows 
were then sorted according to the sum of their frequency within 
the 30% best scored epitopes. After the exclusion of repetitions, 
the 30% cutoff recovered 81 and 285 predicted epitopes of MHC 
I and MHC II, respectively, varying from 12 (at 10 and 15%) 
FigUre 2 | The sequence on which the rosetta’s protocols were used. The total number of complexes generated and the average Interface score (Isc) of it 
are shown. The computational demand of each protocol compared to the FixBB protocol (clock picture), for a single complex (epitope + allele), can also be found. 
Every complex image consists of an example containing a MHC II allele (PDB: 3LQZ) and the epitope #1,677, after each protocol. The MHC II allele is in green, while 
the predicted epitope color range from blue (FixBB) to black (Relax), red (FlexPepDock with 100 solutions), and yellow (FlexPepDock with 500 solutions).
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to 18 (at 25%), within the total 33 alleles (21 for MHC Class I 
and 12 for MHC Class II). Choosing a cutoff larger than 30% 
would not increase significantly the number of occurrences. 
Figure S2 in Supplementary Material shows the plot of percent-
age cutoff for the top ranked candidates, ranging from 10 to 
50%, and Figure S3 in Supplementary Material presents the 
filtering algorithm.
Based on such filtering approach, the 100 best-ranked pairs 
(or 1,764 predicted epitope +  allele complexes) were used at 
the next molecular docking step, with Rosetta’s FlexPepDock 
protocol, because this number of calculations required a viable 
computational demand, about 18-fold lower than the initial set 
of complexes (32,658).
Molecular Docking
The 100 best-ranked pairs after the filtering strategy were then 
used at the molecular docking step with 100 docked solutions 
each. From this set, the top 10 pairs of predicted epitopes, 
FigUre 4 | superimposition of the best solutions for the (a) 4 
predicted Mhc i and (B) 10 Mhc ii epitopes.
FigUre 3 | The filtering approach used in order to reduce the number of complexes calculated at FlexPepDock step. Details can be found in text.
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with the best average Isc among the alleles, were selected for 
an enhanced run of Rosetta’s FlexPepDock protocol with 500 
docked solutions, hence increasing the chance of finding new 
docking solutions with higher affinities for these 10 pairs of 
predicted epitopes.
The final results obtained through the molecular docking of 
these 10 pairs of predicted epitopes defined a total of 4 unique 
9-residue epitopes predicted for MHC I and 10 unique 15-residue 
epitopes predicted for MHC II. Figure 4 shows the superposi-
tion of the best-docked solutions derived from the alleles with 
the highest binding affinity (lowest Isc) to their respective MHC 
targets [alleles with Protein Data Bank (PDB) IDs 4NQV and 
3LQZ for MHC I and MHC II, respectively]. One can see that the 
best docking solutions are quite similar in position, displaying a 
homogeneous result. The way these solutions are positioned are 
consistent with the known binding mechanism for these MHCs, 
as each predicted epitope bound to the correct key anchor residues 
localized within the binding groove of its corresponding MHC 
target (28). The MHC I (Figure  4A) predicted epitopes were 
anchored by residues located at the epitope extremities, while 
the MHC II predicted epitopes (Figure  4B) were anchored by 
residues positioned in the middle. The final selected 14 predicted 
epitopes are those that displayed the best binding affinity among 
the 2,549 candidate epitopes (230 targeting MHC I  +  2,319 
targeting MHC II).
epitope–Mhc interaction Features
Detailed analyses were then conducted in order to identify 
important intermolecular aspects responsible for the affinity of 
these final predicted epitopes to the MHC targets, as follows. 
First, the correlation between the Interface-buried surface area 
(Ibsa), commonly used to measure the size of the macromolecule 
interface (29), and the Isc was evaluated. Figure 5 presents the 
average Ibsa and Isc values for all the complexes (epitope + allele) 
formed by each one of the 33 MHC structures. A strong correla-
tion between Ibsa and Isc was seen, with bigger Ibsa values being 
accompanied by lower (more stable) values for Isc. This was to 
FigUre 5 | correlation between the average interface-buried surface area (ibsa, in square angstroms) and the average interface score (isc). This was 
performed for all the complexes generated with the 33 MHC receptors, after the FlexPepDock protocol (with 500 solutions).
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be expected, since when the contact area between the ligand 
(predicted epitope) and the receptor (allele structure) is larger, 
there are more intermolecular interactions between them stabi-
lizing the complex, with lower (more negative) Isc values. Thus, 
an increase on Ibsa contributes in a favorable way to the binding 
affinity of the complexes, by typically lowering the Isc.
In a similar analysis to the one presented in Figure 5, Figure 6 
shows the correlation between the average Interface hydrogen 
bonds (Ihb) and the average Isc values for all the complexes 
(apitope + allele) formed by each one of the 33 MHC structures. 
As more hydrogen bonds are formed between the receptor and 
the predicted epitope, the Isc value is lower, i.e., the complex has 
a higher binding affinity, emphasizing the fact that the peptides 
bind to the MHC alleles (particularly MHC II) via an “extensive 
hydrogen bond network” (28). To further investigate this cor-
relation, three complexes included in the final results (FPD500) 
were selected and analyzed (Figure 6). It is important to notice 
that the larger Class II epitopes (with 15 residues) have a greater 
natural probability to form hydrogen bonds, because of the 
higher number of residues (two-thirds more). It is also impor-
tant to emphasize that the average Isc, highlighted in Figure 2 as 
“Avrg. score,” can be observed as progressively more negative with 
each successive step of the methodology applied, meaning more 
stable epitope +  allele complexes identified during the in  silico 
procedures.
epitope Tracing
Next, the identity of the 10 highest ranking epitopes was investi-
gated, and they were seen to derive from a total of 4 L. braziliensis 
proteins. The first of these, a conserved hypothetical protein, is 
encoded by a CDS localized to chromosome 34 and encompasses 
at least 4 potential epitopes. Interestingly, the protein segment 
encompassing the 4 15-mer epitopes is 19  aa in linear length. 
Therefore, the four potential epitopes with high affinity for MHC 
I and MHC II molecules are found within this particular seg-
ment, with minor differences between each of these four epitopes, 
but all producing high scores when analyzed by the approaches 
described above. Another conserved hypothetical protein located 
on chromosome 1 encodes at least three epitopes. Here, the three 
epitopes were found in a window 18  aa in length. The third 
protein, found in chromosome 14, encodes two 15-mer epitopes 
located in a window of 16 aa. Finally, the last and largest protein, 
also hypothetical, encodes only one 15-mer epitope. All the genes 
encoding for those proteins are syntenic with other genes from 
trypanosomatids. This indicates that these proteins have evolved 
in the same genetic loci from diverse trypanosomatids, and the 
potential epitopes may induce cross-protection against other 
pathogenic species from the same family.
Validation of Peptide epitopes
In order to have an experimental validation of the results derived 
from the bioinformatic approach, peptides corresponding to 
the 10 highest ranking 15-mer epitopes described above were 
commercially synthesized. These were then used for an evalua-
tion of their ability to induce proliferation of peripheral blood 
mononuclear cells (PBMC) derived from human patients cured 
after treatment. These PBMC were capable of proliferating when 
stimulated with total antigen from L. braziliensis (7.6 ±  6.1), 
FigUre 6 | correlation between the average interface score (isc) and the average interface hydrogen bonds (ihb), for the complexes obtained by the 
FlexPepDock protocol with 500 solutions (FPD500). The blue dots correspond to the MHC II alleles (total of 12), while the red dots correspond to the MHC I 
alleles (total of 21). (a) The best docking solution of the final set of results, showing the predicted epitope that formed the highest number of hydrogen bonds and 
generated the lowest (most stable) Isc. (B) The worst overall solution within the final results, having a low number of hydrogen bonds and the highest (less stable) Isc 
value. (c) One of the worst solutions for a MHC II complex, having a reduced affinity between the allele and the predicted epitope. Only the side chain groups with 
hydrogen bonds are shown. The epitope’s alpha-carbons are highlighted in dark blue.
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and non-stimulated cells had minimal levels of proliferation 
(data not shown). The results from the assays carried out with 
the synthetic peptides are presented as the mean percentage 
of proliferation, with its SD, calculated with the data from the 
proliferation of PBMC derived from 10 patients, when exposed 
to the individual peptides. Peptides 2, 4, 8, 9, and 10 were capa-
ble of stimulating proliferation of many of the PBMC derived 
from the afflicted patients. However, no significant difference 
was observed when the mean proliferation values obtained for 
these peptides with the PBMC from the 10 patients was com-
pared with the mean values derived from the data with PBMC 
from the control group, consisting of five healthy volunteers. In 
contrast, significant statistical differences were observed for the 
mean PBMC proliferation results between samples from treated 
patients and control volunteers for the assays carried out with 
peptides 1, 3, 5, 6, and 7 (Figure  7). These five peptides are 
derived from three of the four L. braziliensis proteins described 
above, confirming that the positive response is not associated 
with one specific protein. The possibility that the improved 
results from some peptides might also be associated with a 
stronger response from a reduced number of individuals was 
also investigated. The PBMC from two patients did respond 
better to a greater number of peptides, four in all, but these 
include peptides included among both groups described above. 
In all, the PBMC proliferation data highlight the potential of 
the computational approaches used for epitope selection and 
indicate that some of the synthetic peptides tested would be rec-
ognized by the immune system to mount a protective immune 
response.
DiscUssiOn
So far, different approaches have tried to address the lack of an 
anti-Leishmania vaccine capable of being effectively used against 
the leishmaniasis. However, most of the vaccines under develop-
ment have failed in very early assays, due to factors such as poor 
antigen response, absence of good animal models, and lack of 
standardization (30). An ideal vaccine should also be capable of 
stimulating a promiscuous response against different Leishmania 
species, but generally only one species has been considered at a 
time. Moreover, only a few papers have described predictions 
of T cell epitopes from Leishmania spp. proteomes (31–35). 
Most of these have focused on epitopes, which bind to MHC I, 
with a focus on CD8+ T cell response and not considering the 
induction of a response mediated by CD4+ T cells (31, 32, 35, 
36). CD8+ T  cells have a major role in protecting against CL, 
but evidence has been provided that they may also exacerbate 
and compromise the disease outcome (37). In this context, we 
have searched for natural epitopes that would stimulate both 
CD4+ and CD8+ T cells, in order to establish a more balanced 
response that could favor the prevention of disease progression. 
However, development of CD4+ T cell predicted epitopes is still 
a challenge, since we do not fully understand the epitope motifs 
that bind to the MHC II groove, most of the peptides may not 
be naturally processed by APCs, and the positional alignment 
is critical for the prediction (38, 39). To overcome these issues, 
the epitopes predicted here were tested through different criteria 
in order to define a final set of peptides. One of these criteria 
was the capacity to bind with high affinity to both MHC I and 
MHC II, as demonstrated by the high scores of the complexes and 
the elevated number of hydrogen bonds, for example. Thus, it is 
expected that, during natural processing by APCs, these peptides 
could bind either to MHC I or MHC II or be able to bind both 
molecules. We hypothesized that the differences observed in 
the cell proliferation are a consequence of the number of T cells 
present in the peripheral blood of recovered patients. In addition, 
these peptides may differ in how they are presented and activate 
T cells since they have different linear sequences.
In terms of target MHC molecules, this work has crucially 
focused in simulating peptide epitopes with different allele 
supertypes expressed by different human populations. Allele 
selection considered their distribution across the globe and other 
important parameters, such as the promiscuity of the selected 
peptides to which they bind and PDB crystallized structures. To 
do so, most of the work was based on human MHC alleles and in 
order to reduce bias due to MHC multiplicity, allele supertypes 
were used (40–42). Supertypes share specific residues at some 
anchor positions, thus, they are capable of binding to overlapping 
groups of peptides (43). It is important to consider the human 
MHC molecules, since the purpose of the work is to develop 
a vaccine that would be applied to humans. Previous works 
have already helped the search for potential epitopes that could 
bind to murine MHC, since it is the most used experimental 
model for preclinical assays, testing potential vaccines against 
leishmaniasis (23, 36). Most of the in silico developed peptides 
based on the murine model, however, may fail to translate good 
results to humans, due to the huge differences between human 
and mouse immune responses. All the computational efforts 
performed here were therefore dedicated to simulate peptides 
with human MHC alleles.
One of the major problems of bioinformatics these days is 
the huge amount of data generated. Linear epitope predictions 
using predicted proteomes provide a large number of potential 
epitopes, which cannot possibly be tested. Therefore, this large 
number must be reduced into a feasible number of epitopes, which 
can be experimentally tested for their immunogenicity. Thus, 
the option here to solve this issue was for molecular modeling 
protocols, mainly through the application of molecular docking 
approaches, adding another layer of strength to the data. Here, it 
has been shown that the best-ranked peptide epitopes are clearly 
those that establish the highest number of molecular interactions 
(like hydrogen bonds and hydrophobic contacts, for example) 
with the chemical groups in the MHC groove. Nevertheless, the 
in silico methods employed and some decisions taken during the 
process may have imposed some limitations. One of these is that, 
the tools available to predict linear epitopes use learning machine 
techniques, which have a huge dependency on training dataset. 
However, those tools are not currently trained with experi-
mental data from trypanosomatids, such as L. braziliensis (27). 
Additionally, other factors have also guided the decisions, such 
as the exclusion of proteins with more than one transmembrane 
helix that might be difficult for further expression, and exclu-
sion of proteins conserved but with high similarity with human 
sequences, which is not desired for a vaccine. Moreover, one 
FigUre 7 | continued
10
e Silva et al. T Cell Epitopes in the Proteome of Leishmania braziliensis
Frontiers in Immunology | www.frontiersin.org August 2016 | Volume 7 | Article 327
limitation related to structural approach is the limited diversity 
of HLA structure alleles available on the PDB bank. Here, just 
21 and 12 alleles of MHCI and MHCII, respectively, were tested. 
This aspect could affect the performance of the method used here.
Based on the results presented so far, it seems that the pro-
posed combination of approaches is consistent enough to be 
applied in cases of reverse vaccinology, when there is a large 
quantity of candidate epitopes to be tested. The strategy of 
FigUre 7 | comparison of the proliferation data from PBMc derived from the cutaneous leishmaniasis post treatment (PT) patients with the PBMc 
proliferation data from the control group, in response to different peptides. The asterisk indicates significant differences (p < 0.05) between patients and 
control group. The horizontal bars represent the mean values for each group. The median percentage levels and the corresponding SD for each group tested are 
described below.
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distributed computing (computational grid) alongside the filter-
ing algorithms has turned an unpractical problem, into a feasible 
task, done in weeks. Moreover, in the context of leishmaniasis, 
the results of this research identified peptide epitopes with high 
potential to stimulate the immune system to develop a protective 
response.
MaTerials anD MeThODs
linear epitope Prediction
Proteome Retrieval and Conservancy
The available proteomes (from L. braziliensis, Leishmania major, 
and L. infantum) were downloaded from TriTrypDB (44) and 
used to perform, in parallel, different bioinformatics analyses. 
Only protein sequences from L. braziliensis with more than 60% 
conservancy with other Leishmania species verified through 
BLAST protein alignment were considered for epitope analysis. 
This parameter was taken into account since an ideal vaccine 
should be capable to induce protection in individuals against as 
many species as possible.
MHC Class I and MHC Class II Prediction Tools and 
Binding Affinity Prediction
NetMHC and NetCTL tools were used for a MHC I predictions, 
while MHC II predictions were made using the NetMHCII tool 
for the most prevalent allele supertypes (45–47). Both NetMHC 
and NetCTL are epitope predictors; however, NETMHC just 
predicts the epitope, while NETCLC also considers other predic-
tions, such as the transport efficiency prediction mediated by the 
transporter associated with antigen processing (TAP) protein and 
the C-terminal proteasomal cleavage prediction. The cutoff score 
defined to select peptides with high affinity for those tools was 
≥1 in order to maximize the number of true positive predictions.
Similarity and Biological Features of Protein 
Candidates
In order to exclude protein candidates with high degree of 
similarity with proteins of humans and mice, the BLAST 
sequence alignment tool (48) was used to compare parasite 
protein sequences against host protein sequences. Proteins with 
degree of similarity equal or higher than 40% with human or 
mice proteins were excluded from the next steps. Moreover, 
transmembrane helix and subcellular localization predictions 
were performed using the TMHMM tool (49) and WoLF 
PSORT (50), respectively.
All the data obtained after running the methods described 
above were deposited in a relational database, which is man-
aged using MySQL as a database management system (DBMS). 
Parsers and algorithms in PERL and SQL languages were devel-
oped in order to access and integrate the results deposited in the 
databank.
Clusterization
An in-house algorithm based on BLAST alignment results was 
developed in order to group the data with high similarity. A 
threshold of 60% of identity and 100% of coverage between any 
two epitopes were used in order to cluster them in the same group. 
In addition, group selection was performed based on selective 
criteria: peptide epitopes with high affinity predicted for at least 
three different allele of either MHC Class I or MHC Class II, or 
peptide epitopes derived from at least three different proteins.
Molecular Modeling approach
Preparing MHC Structures from PDB
The structures from the 33 different alleles of MHC I (21 PDB 
structures: 2HJL, 3C9N, 3HCV, 3KPP, 3L3D, 3RL1, 3VCL, 3VFS, 
3 × 11, 4F7M, 4G8G, 4HWZ, 4JQX, 4MJ5, 4MJI, 4NQV, 4O2C, 
4QRR, 4QRU, 4WU5, and 4XXC) and MHC II (12 PDB struc-
tures: 1A6A, 1BX2, 1H15, 1S9V, 1UVQ, 1YMM, 2NNA, 2Q6W, 
3C5J, 3LQZ, 3PL6, and 3WEX) were downloaded from RCSB 
PDB (51). These structures were then prepared by removing 
the water molecules, ligands, and duplicated residues or alleles. 
Furthermore, using the PyMol (52) software in build mode, 
the co-crystallized small peptide chain, for each structure, was 
modified to have the same length as the predicted peptides used 
in this work (9 residues for MHC I and 15 residues for Class II). 
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In addition, each non-canonical amino acid found in the co-
crystallized peptide was manually mutated to alanine.
An in-house developed software named GriDoMol was then 
used to prepare and submit into a computational grid environ-
ment all the in silico procedures required to combine the MHC 
structures to the predicted epitopes and to compile the results 
obtained at each step into formatted datasheets. This computa-
tional grid environment was assembled, in our laboratory, by 
using eight computers, each containing 2× Intel Xeon quadcore 
(total of eight cores per computer) chipset and 16  GB RAM 
memory.
Producing MHC–Epitope Complexes
The sequence of steps on which the Rosetta framework (53) 
protocols were used can be found in Figure 2. For the replace-
ment of the co-crystallized peptides for each one of the predicted 
epitopes, the Rosetta’s FixBB protocol, available within the Rosetta 
framework, was used. However, the Rosetta’s FixBB protocol does 
not move the backbone atoms, and thus the replacement of the 
co-crystallized peptide for a new one may produce unstable final 
conformations. Therefore, the Rosetta’s Relax protocol was used, 
right after the FixBB protocol, in order to energetically stabilize 
each one of the new epitopes. Moreover, all the MHC receptor’s 
residues have been locked unmovable to prevent conformational 
changes on the receptor side, while only the epitope’s residues 
were allowed to move and rotate toward a more stable conforma-
tion in the chemical neighborhood.
In order to quantify the binding affinity between receptors 
and predicted epitopes, at this particular step, the score function 
named Isc was chosen from the Rosetta’s FlexPepDock protocol 
(54), which is the sum over the energetic contributions of the 
interface residues on both the receptor and the predicted epitope. 
Hence, all the 32,658 structures obtained by the application of the 
Rosetta’s Relax protocol were only rescored using the Rosetta’s 
FlexPepDock protocol, in order to obtain the Isc values, but 
keeping the same structure obtained by Relax protocol (i.e., 
without any change on the atomic coordinates). In other words, 
the rescore procedure just recomputed the energy (with a better 
scoring function) at the same geometry, without perturbing the 
chemical system.
Scoring Potential Epitopes through Molecular 
Docking
While each run of the FixBB or Relax protocols takes a few 
seconds to generate the result, each run of the FlexPepDock 
protocol, using the default setup (100 docked solutions obtained 
as result), takes hours to complete. Thus, a filtering strategy had 
to be adopted in order to select the most promising predicted 
epitopes, based on their Isc scores (obtained by rescoring, as 
mentioned above) with receptors and the frequency of affinity 
observed along different MHC receptor structures.
The Rosetta’s FlexPepDock protocol, using the refinement 
approach, was applied to perform the molecular docking, 
allowing the full flexibility for the predicted epitope and the 
side chain flexibility for the residues at the receptor’s interface. 
This procedure searched for the predicted epitopes with the 
best binding affinities for MHC’s alleles. For each predicted 
epitope, the best docking solutions were selected according to 
the Isc. At the end, the predicted epitopes were ranked by the 
average Isc of their solutions along the MHC’s alleles, granting 
an overall view of each epitope’s average affinity. From the list 
of 100 pairs previously described, the first 10 pairs of predicted 
epitopes with the best average Isc among the alleles have 
been selected for an enhanced run of Rosetta’s FlexPepDock 
protocol, increasing the number of generated structures from 
100 to 500. The computational cost of such calculation (500 
docked solutions) was about 5 times greater than the default 
100 docked solutions.
Validation of Peptide epitopes
Synthetic Peptides and Storage
Peptides corresponding to the top 10 ranked 15-mer peptides 
were synthesized (Genome Biotechnology, Brazil). Linear 
peptides were purified through a high performance liquid chro-
matography (HPLC) approach with a final purity greater than 
95%. All the synthetic peptides were individually resuspended in 
DMSO and stored at −80°C until use.
Sampling and Isolation of Peripheral Blood 
Mononuclear Cells
All individuals included in this research signed a written informed 
consent before blood collection, following recommendations 
of the Ethics Committee from the Centro de Pesquisas Aggeu 
Magalhães (CPqAM-FIOCRUZ, Project: 522.964). From each 
individual, a total of 30  mL of peripheral blood was collected 
by venipuncture in sodium-heparin tubes (Vacuette, USA). 
The blood was diluted (1:1 v/v) with phosphate-buffered saline 
(PBS, pH 7.2) and deposited onto the Ficoll–Paque PLUS density 
(1.077  g/mL) gradient (GE Healthcare, USA) and centrifuged. 
Subsequently, the PBMC layer was individually removed and 
washed twice with PBS.
CFDA-SE Labeling and Cell Culture
About 4 × 106 cells were resuspended in 1 mL of PBS contain-
ing 2  μM of carboxyfluorescein diacetate succinimidyl ester 
(CFDA-SE, Invitrogen, USA) and incubated at 37°C for 10 min. 
The CFDA-SE concentration was previously titrated in order to 
prevent inhibition of cell proliferation or cell death. After incuba-
tion, cell labeling was quenched with 1 mL of ice-cold (4°C) RPMI 
1,640 containing 2 mM of l-glutamine, 50 mg/L of gentamicin 
sulfate, and 2 mg/L of amphotericin B, supplemented with 10% 
fetal bovine serum (both Cultilab reagents, Brazil). The cells were 
pelleted and washed with PBS followed by resuspension in 1 mL 
of RPMI 1,640 supplemented at a density of 2 ×  106  cells/mL. 
The PBMC were plated in 96-well U bottom plates (BD Falcon) 
at a density of 2 × 105 cells/well with 20 μg/mL of each peptide. 
These cells were then incubated at 37°C with 5% CO2 for 96 h. 
For each patient or control volunteer tested, non-stimulated and 
phytohemagglutinin (PHA)-stimulated cells were evaluated as 
intra-experimental controls.
Flow Cytometry Analysis
The analyses were performed on a FACScalibur flow cytometer 
(Becton Dickinson Company, USA) equipped with an argon laser 
13
e Silva et al. T Cell Epitopes in the Proteome of Leishmania braziliensis
Frontiers in Immunology | www.frontiersin.org August 2016 | Volume 7 | Article 327
reFerences
1. WHO. Neglected Tropical Diseases, Hidden Successes, Emerging Opportunities. 
Geneva: World Health Organization (2009). 59 p.
2. Hotez PJ, Ferris MT. The antipoverty vaccines. Vaccine (2006) 24(31–
32):5787–99. doi:10.1016/j.vaccine.2006.05.008 
3. Collier P. The Bottom Billion: Why the Poorest Countries Are Failing and What 
Can Be Done about it. Oxford: Oxford University Press (2007).
4. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et  al. 
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 
regions, 1990-2010: a systematic analysis for the Global Burden of Disease 
Study 2010. Lancet (2012) 380:2197–223. doi:10.1016/S0140-6736(12)61689-4 
5. Pigott DM, Bhatt S, Golding N, Duda KA, Battle KE, Brady OJ, et al. Global 
distribution maps of the leishmaniases. Elife (2014) 3:e02851. doi:10.7554/
eLife.02851 
6. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis 
worldwide and global estimates of its incidence. PLoS One (2012) 7(5):e35671. 
doi:10.1371/journal.pone.0035671 
7. Beaumier CM, Gillespie PM, Hotez PJ, Bottazzi ME. New vaccines for 
neglected parasitic diseases and dengue. Transl Res (2013) 162(3):144–55. 
doi:10.1016/j.trsl.2013.03.006 
8. Brito MEF, Andrade MS, Almeida EL, Medeiros AC, Werkhäuser RP, de 
Araújo AI, et al. Occupationally acquired American cutaneous Leishmaniasis. 
Case Rep Dermatol Med (2012) 2012:279517. doi:10.1155/2012/279517 
9. de Assis-Souza M, Castro MC, de Oliveira AP, de Almeida AF, de Almeida 
TM, de Campos LR, et  al. Cytokines and NO in American tegumentary 
leishmaniasis patients: profiles in active disease, after therapy and in self-
healed individuals. Microb Pathog (2013) 57:27–32. doi:10.1016/j.micpath. 
2013.02.004 
10. Sacks DL. Vaccines against tropical parasitic diseases: a persisting answer to 
a persisting problem. Nat Immunol (2014) 15(5):403–5. doi:10.1038/ni.2853 
11. Oghumu S, Lezama-Dávila CM, Isaac-Márquez AP, Satoskar AR. Role of 
chemokines in regulation of immunity against leishmaniasis. Exp Parasitol 
(2010) 126(3):389–96. doi:10.1016/j.exppara.2010.02.010 
12. Birnbaum R, Craft N. Innate immunity and Leishmania vaccination strategies. 
Dermatol Clin (2011) 29(1):89–102. doi:10.1016/j.det.2010.08.014 
13. da Silva Santos C, Brodskyn CI. The role of CD4 and CD8 T cells in human 
cutaneous leishmaniasis. Front Public Health (2014) 2:165. doi:10.3389/
fpubh.2014.00165 
14. Brelaz-de-Castro MC, de Almeida AF, de Oliveira AP, de Assis-Souza M, da 
Rocha LF, Pereira VR. Cellular immune response evaluation of cutaneous 
leishmaniasis patients cells stimulated with Leishmania (Viannia) braziliensis 
antigenic fractions before and after clinical cure. Cell Immunol (2012) 
279(2):180–6. doi:10.1016/j.cellimm.2012.11.006 
15. Souza MA, Almeida TM, Castro MCAB, Oliveira-Mendes AP, Almeida AF, 
Oliveira BC, et al. American tegumentary leishmaniasis: mRNA expression 
for Th1 and Treg mediators are predominant in patients with recent active 
disease. Immunobiology (2016) 221(2):253–9. doi:10.1016/j.imbio. 
2015.08.009 
16. Bennett CL, Misslitz A, Colledge L, Aebischer T, Blackburn CC. Silent infec-
tion of bone marrow-derived dendritic cells by Leishmania mexicana amas-
tigotes. Eur J Immunol (2001) 31:876–83. doi:10.1002/1521-4141(200103)31: 
3<876::AID-IMMU876>3.0.CO;2-I 
17. Xin L, Li Y, Soong L. Role of interleukin-1beta in activating the CD11c(high) 
CD45RB-dendritic cell subset and priming Leishmania amazonensis- 
specific CD4+ T cells in vitro and in vivo. Infect Immun (2007) 75:5018–26. 
doi:10.1128/IAI.00499-07 
18. Vargas-Inchaustegui DA, Xin L, Soong L. Leishmania braziliensis infection 
induces dendritic cell activation, ISG15 transcription, and the generation 
of protective immune responses. J Immunol (2008) 180(11):7537–45. 
doi:10.4049/jimmunol.180.11.7537 
19. Inaba K, Turley S, Iyoda T, Yamaide F, Shimoyama S, Reis e Sousa C. The 
formation of immunogenic major histocompatibility complex class II 
peptide ligands in lysosomal compartments of dendritic cells is regulated 
by inflammatory stimuli. J Exp Med (2000) 191(6):927–36. doi:10.1084/jem. 
191.6.927 
20. Flower DR, Macdonald IK, Ramakrishnan K, Davies MN, Doytchinova IA. 
Computer aided selection of candidate vaccine antigens. Immunome Res 
(2010) 6(Suppl 2):S1. doi:10.1186/1745-7580-6-S2-S1 
21. Patronov A, Doytchinova I. T-cell epitope vaccine design by immunoinfor-
matics. Open Biol (2013) 8:3. doi:10.1098/rsob.120139 
22. John L, John GJ, Kholia T. A reverse vaccinology approach for the identifi-
cation of potential vaccine candidates from Leishmania spp. Appl Biochem 
Biotechnol (2012) 167(5):1340–50. doi:10.1007/s12010-012-9649-0 
23. Agallou M, Athanasiou E, Koutsoni O, Dotsika E, Karagouni E. Experimental 
validation of multi-epitope peptides including promising MHC class I- and 
II-restricted epitopes of four known Leishmania infantum proteins. Front 
Immunol (2014) 5:268. doi:10.3389/fimmu.2014.00268 
24. Kamhawi S, Oliveira F, Valenzuela JG. Using humans to make a human 
Leishmaniasis vaccine. Sci Trans Med (2014) 6(234):234fs18. doi:10.1126/
scitranslmed.3009118 
25. Oyarzun P, Kobe B. Recombinant and epitope-based vaccines on the road to 
the market and implications for vaccine design and production. Hum Vaccin 
Immunother (2016) 12(3):763–7. doi:10.1080/21645515.2015.1094595 
26. Teh-Poot C, Tzec-Arjona E, Martínez-Vega P, Ramirez-Sierra MJ, Rosado-
Vallado M, Dumonteil E. From genome screening to creation of vaccine 
against Trypanosoma cruzi by use of immunoinformatics. J Infect Dis (2015) 
211(2):258–66. doi:10.1093/infdis/jiu418 
27. Resende DM, Rezende AM, Oliveira NJD, Batista ICA, Corrêa-Oliveira  R, 
Reis AB, et  al. An assessment on epitope prediction methods for pro-
tozoa genomes. BMC Bioinformatics (2012) 13:309. doi:10.1186/1471- 
2105-13-309 
(wavelength 488 nm). Fluorescence of 20,000 lymphocyte gated 
events, based on scatter parameters of size and granulosity, was 
acquired. The data were analyzed and treated with FlowJo v10.1 
(Tree Star Inc., USA). Non-stimulated cells were used during 
the analysis for setting quadrant parameters and to set the basal 
level of lymphocyte proliferation. For the statistical analysis, 
the data were analyzed with non-parametric Mann–Whitney 
U-test. Differences were considered statistically significant when 
p < 0.05.
aUThOr cOnTriBUTiOns
Conceived and designed the methods: RS, MH, AR, and VP. 
Performed the in  silico approaches: RS, LF, MH, and AR. 
Performed the epitope validation: RS, VP, MB, BO, and AS. 
Analyzed the data: RS, LF, MH, Od-M-N, AR, VP, MB, BO, and 
AS. Wrote the paper: RS, LF, MH, Od-M-N, AR, and VP.
acKnOWleDgMenTs
LF is the recipient of a doctoral fellowship received from the 
“Fundação de Amparo à Ciência e Tecnologia do Estado de 
Pernambuco” (FACEPE). MH, Od-M-N, and VP acknowledge 
research fellowships received from the “Conselho Nacional de 
Desenvolvimento Científico e Tecnológico” (CNPq).
FUnDing
This study was supported by Chamada MCTI/CNPq/MS-SCTIE – 
Decit No. 40/2012 – Pesquisa em Doenças Negligenciadas. 
Processo No.: 404259/2012.
sUPPleMenTarY MaTerial
The Supplementary Material for this article can be found online at 
http://journal.frontiersin.org/article/10.3389/fimmu.2016.00327
14
e Silva et al. T Cell Epitopes in the Proteome of Leishmania braziliensis
Frontiers in Immunology | www.frontiersin.org August 2016 | Volume 7 | Article 327
28. Holland CJ, Cole DK, Godkin A. Re-directing CD4+ T cell responses with 
the flanking residues of MHC class II-bound peptides: the core is not enough. 
Front Immunol (2013) 4:172. doi:10.3389/fimmu.2013.00172 
29. Chakravarty D, Guharoy M, Robert CH, Chakrabarti P, Janin J. Reassessing 
buried surface areas in protein-protein complexes. Protein Sci (2013) 
22:1453–7. doi:10.1002/pro.2330 
30. Working Group on Research Priorities for Development of Leishmaniasis 
Vaccines, Costa CH, Peters NC, Maruyama SR, de Brito EC Jr, Santos IK. 
Vaccines for the leishmaniases: proposals for a research agenda. PLoS Negl 
Trop Dis (2011) 5(3):e943. doi:10.1371/journal.pntd.0000943 
31. Guerfali FZ, Ben-Abdallah H, Sghaier RM, Ben-Aissa K, Mkannez G, Attia H, 
et  al. An in  silico immunological approach for prediction of CD8+ T cell 
epitopes of Leishmania major proteins in susceptible BALB/c and resistant 
C57BL/6 murine models of infection. Infect Genet Evol (2009) 9(3):344–50. 
doi:10.1016/j.meegid.2008.02.011 
32. Seyed N, Zahedifard F, Safaiyan S, Gholami E, Doustdari F, Azadmanesh K, 
et al. In silico analysis of six known Leishmania major antigens and in vitro 
evaluation of specific epitopes eliciting HLA-A2 restricted CD8 T cell 
response. PLoS Negl Trop Dis (2011) 5(9):e1295. doi:10.1371/journal.pntd. 
0001295 
33. Nico D, Claser C, Borja-Cabrera GP, Travassos LR, Palatnik M, Soares IS, 
et al. Adaptive immunity against Leishmania nucleoside hydrolase maps its 
c-terminal domain as the target of the CD4+ T cell-driven protective response. 
PLoS Negl Trop Dis (2010) 4(11):e866. doi:10.1371/journal.pntd.0000866 
34. Pingel S, Launois P, Fowell DJ, Turck CW, Southwood S, Sette A, et al. Altered 
ligands reveal limited plasticity in the T cell response to a pathogenic epitope. 
J Exp Med (1999) 189(7):1111–20. doi:10.1084/jem.189.7.1111 
35. Rezvan H, Rees R, Ali S. Immunogenicity of MHC class I peptides derived 
from Leishmania mexicana Gp63 in HLA-A2.1 transgenic (HHDII) and 
BALB/C mouse models. Iran J Parasitol (2012) 7(4):27–40. 
36. Duarte A, Queiroz ATL, Tosta R, Carvalho AM, Barbosa CH, Bellio M, 
et  al. Prediction of CD8+ epitopes in Leishmania braziliensis proteins 
using EPIBOT: in  silico search and in  vivo validation. PLoS One (2015) 
10(4):e0124786. doi:10.1371/journal.pone.0124786 
37. Novais FO, Scott P. CD8+ T cells in cutaneous leishmaniasis: the good, the 
bad, and the ugly. Semin Immunopathol (2015) 37(3):251–9. doi:10.1007/
s00281-015-0475-7.2015 
38. Oyarzún P, Ellis JJ, Bodén M, Kobe B. PREDIVAC: CD4+ T-cell epitope pre-
diction for vaccine design that covers 95% of HLA class II DR protein diversity. 
BMC Bioinformatics (2013) 14:52. doi:10.1186/1471-2105-14-52 
39. Mou Z, Li J, Boussoffara T, Kishi H, Hamana H, Ezzati P, et al. Identification 
of broadly conserved cross-species protective Leishmania antigen and its 
responding CD4+ T cells. Sci Transl Med (2015) 7(310):310ra167. doi:10.1126/
scitranslmed.aac5477 
40. Doytchinova IA, Guan P, Flower DR. Identifying human MHC supertypes 
using bioinformatic methods. J Immunol (2004) 172(7):4314–23. doi:10.4049/
jimmunol.172.7.4314 
41. Sidney J, Peters B, Frahm N, Brander C, Sette A. HLA class I super-
types: a revised and updated classification. BMC Immunol (2008) 9:1. 
doi:10.1186/1471-2172-9-1 
42. Wang Y, Qiu M, Yang J, Zhao X, Wang Y, Zhu Q, et al. Sequence variations 
of the MHC class I gene exon 2 and exon 3 between infected and uninfected 
chicken challenged with Marek’s disease virus. Infect Genet Evol (2014) 
21:103–9. doi:10.1016/j.meegid.2013.10.020 
43. Francisco RS, Buhler S, Nunes JM, Bitarello BD, França GS, Meyer D, et al. 
HLA supertype variation across populations: new insights into the role of 
natural selection in the evolution of HLA-A and HLA-B polymorphisms. 
Immunogenetics (2015) 67(11–12):651–63. doi:10.1007/s00251-015-0875-9 
44. Aslett M, Aurrecoechea C, Berriman M, Brestelli J, Brunk BP, Carrington M, 
et al. TriTrypDB: a functional genomic resource for the Trypanosomatidae. 
Nucleic Acids Res (2010) 38:457–62. doi:10.1093/nar/gkp851 
45. Larsen MV, Lundegaard C, Lamberth K, Buus S, Lund O, Nielsen M. Large-
scale validation of methods for cytotoxic T-lymphocyte epitope prediction. 
BMC Bioinformatics (2007) 8:424. doi:10.1186/1471-2105-8-424 
46. Nielsen M, Lundegaard C, Worning P, Lauemoller SL, Lamberth K, Buus S, 
et  al. Reliable prediction of T-cell epitopes using neural networks with 
novel sequence representations. Protein Sci (2003) 12:1007–17. doi:10.1110/
ps.0239403 
47. Nielsen M, Lund O. NN-align. An artificial neural network-based alignment 
algorithm for MHC class II peptide binding prediction. BMC Bioinformatics 
(2009) 10:296. doi:10.1186/1471-2105-10-296 
48. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment 
search tool. J Mol Biol (1990) 215:403–10. doi:10.1016/S0022-2836(05) 
80360-2 
49. Krogh A, Larsson B, von Heijne G, Sonnhammer EL. Predicting transmem-
brane protein topology with a hidden Markov model: application to complete 
genomes. J Mol Biol (2001) 305(3):567–80. doi:10.1006/jmbi.2000.4315 
50. Horton P, Park KJ, Obayashi T, Fujita N, Harada H, Adams-Collier CJ, 
et al. WoLF PSORT: protein localization predictor. Nucleic Acids Res (2007) 
35:585–7. doi:10.1093/nar/gkm259 
51. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et  al. 
The Protein Data Bank. Nucleic Acids Res (2000) 28:235–42. doi:10.1093/
nar/28.1.235 
52. DeLano WL. PyMOL molecular viewer: updates and refinements. The 238th 
ACS National Meeting 238. Washington, DC (2009).
53. Leaver-Fay A, Tyka M, Lewis SM, Lange OF, Thompson J, Jacak R, et  al. 
ROSETTA3: an object-oriented software suite for the simulation and design 
of macromolecules. Methods Enzymol (2011) 487:545–74. doi:10.1016/
B978-0-12-381270-4.00019-6 
54. Raveh B, London N, Schueler-Furman O. Sub-angstrom modeling of 
complexes between flexible peptides and globular proteins. Proteins (2010) 
78(9):2029–40. doi:10.1002/prot.22716 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 e Silva, Ferreira, Hernandes, de Brito, de Oliveira, da Silva, 
de-Melo-Neto, Rezende and Pereira. This is an open-access article distributed under 
the terms of the Creative Commons Attribution License (CC BY). The use, distribu-
tion or reproduction in other forums is permitted, provided the original author(s) 
or licensor are credited and that the original publication in this journal is cited, in 
accordance with accepted academic practice. No use, distribution or reproduction is 
permitted which does not comply with these terms.
